
Opinion|Videos|May 10, 2024
Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
4
As Milestone Nears, an Early Investigator Reflects on Lessons of Imatinib
5














































